Cancer stem cells (CSCs) are a small population of cancer cells that exhibit stemness. These cells contribute to cancer metastasis, treatment resistance, and relapse following therapy; therefore, they may cause malignancy and reduce the success of cancer treatment. Nuclear factor kappa B- (NF-κB-) mediated inflammatory responses increase stemness in cancer cells, and CSCs constitutively exhibit higher NF-κB activation, which in turn increases their stemness. These opposite effects form a positive feedback loop that further amplifies inflammation and stemness in cancer cells, thereby expanding CSC populations in the tumor. Toll-like receptors (TLRs) activate NF-κB-mediated inflammatory responses when stimulated by carcinogenic microbes and endogenous molecules released from cells killed during cancer treatment. NF-κB activation by extrinsic TLR ligands increases stemness in cancer cells. Moreover, it was recently shown that increased NF-κB activity and inflammatory responses in CSCs may be caused by altered TLR signaling during the enrichment of stemness in cancer cells. Thus, the activation of TLR signaling by extrinsic and intrinsic factors drives a positive interplay between inflammation and stemness in cancer cells.
National Health Research InstitutesIM-105-PP-02Ministry of Science and TechnologyMOST104-3011-B010-001MOST 104-2314-B-400-024MOST 105-2320-B-400-013-MY31. Introduction
Inflammation is a hallmark of cancer development [1, 2]. Chronic inflammation caused by exposure to environmental agents, infection, genetic disease, and metabolic disorders is closely associated with several tumors, including lung carcinoma, hepatocellular carcinoma (HCC), gastric cancer, cervical cancer, colorectal cancer, Hodgkin’s disease, and multiple myelomas [3, 4].
The tumor microenvironment comprises cancer cells, cancer stem cells (CSCs), endothelial cells, and immune cells, such as tumor-associated macrophages, tumor-associated neutrophils, lymphocytes, and other stromal cells, such as cancer-associated fibroblasts [2, 5]. Inflammatory stimuli, such as the toll-like receptor (TLR) agonists, tumor necrosis factor- (TNF-) α, and interleukin- (IL-) 1, activate NF-κB in tumor cells [6, 7]. Activated NF-κB induces the transcription of multiple proinflammatory genes and is a key mediator of acute and chronic inflammatory responses in tumor cells and the tumor microenvironment [3, 8]. NF-κB-mediated proinflammatory programs link cancer-related inflammation with carcinogenic processes, including tumor initiation, tumor promotion, and metastasis. NF-κB induces the expression of genes that regulate apoptosis, angiogenesis, proliferation, survival, and cancer cell invasion. These NF-κB-mediated responses also rehabilitate the inflammatory tumor microenvironment, further supporting tumor progression [9–11].
CSCs are a small population of cancer cells with enriched stemness and tumor-initiating ability in the tumor microenvironment. CSCs possess self-renewal and differentiation abilities, which promote tumor progression and metastasis and are responsible for treatment resistance and cancer relapse [12–16]. In addition to supporting angiogenesis, proliferation, and cancer cell survival, NF-κB-mediated inflammatory responses also support CSC expansion. NF-κB activation induces the expression of stemness-associated genes and regulators of the epithelial-mesenchymal transition (EMT) in cancer cells, thereby generating a CSC phenotype [17–19]. In contrast, together with increased stemness, CSCs exhibit an elevated expression of inflammatory genes due to elevated NF-κB activation [20–23]. This interplay between inflammation and stemness could enhance these two properties of cancer cells to further expand the CSC population. CSCs may cause malignancy and reduce the success of cancer treatments; therefore, the molecular mechanisms underlying the interplay between inflammation and stemness should be further investigated in cancer cells.
TLRs are a family of receptors that sense pathogen-associated molecular patterns (PAMPs) of microbes and danger-associated molecular patterns (DAMPs) released from damaged tissues or cells killed during different cancer therapies [24–26]. TLR signaling triggers NF-κB activation and inflammatory responses [27, 28]. In this review, we discuss the current knowledge on the function and mechanisms of TLR signaling in the bidirectional interplay between inflammation and stemness in cancer cells.
2. TLRs
Toll is a type I transmembrane receptor that was originally identified in Drosophila for its involvement in embryo development [29]. In the adult fly, toll plays a crucial role in innate immune responses to microbial infections. Thirteen TLRs have been identified in mammals, 10 of which (TLR1–TLR10) are expressed in humans. The 10 human TLRs share common structural features: an extracellular domain comprising multiple leucine-rich repeats, a transmembrane region, and a highly conserved cytoplasmic toll/IL-1 receptor (TIR) domain [30–32].
The cellular location and ligands of these TLRs are summarized in Table 1. TLR3, TLR7, TLR8, and TLR9 are localized in intracellular vesicles, including endosomes, whereas others are localized on the cell surface. These TLRs play essential roles in the innate recognition of PAMPs of microbes. TLR2 recognizes a broad range of microbial components, including peptidoglycan, lipoteichoic acids, lipoproteins, lipoarabinomannan, glycophosphatidylinositol anchors, porins, and zymosan [33–39]. TLR2 can form heterodimers with TLR1 or TLR6 to differentially recognize different microbial products. The TLR2–TLR6 complex preferentially recognizes mycoplasma macrophage-activating lipopeptide 2, whereas the TLR2-TLR1 heterodimer more specifically recognizes bacterial lipoproteins and triacyl lipopeptides [40–42]. TLR3 recognizes double-stranded RNA (dsRNA), which is generated during viral replication within infected cells [43]. TLR4 was the first mammalian TLR to be identified [44] and is the major receptor involved in recognizing lipopolysaccharides on the outer membrane of gram-negative bacteria [45]. TLR5 recognizes flagellin, a component of bacterial flagella [46]. TLR7–TLR9 comprised a TLR subfamily with members containing longer extracellular domains [47, 48]. TLR7 and TLR8 recognize single-stranded RNA viruses, such as the vesicular stomatitis virus or the influenza virus [49, 50]. TLR9 is essential for the response to microbial unmethylated CpG DNA. Most CpG sites in mammalian cells, but not in microbes, are methylated; therefore, unmethylated CpG DNA may indicate a microbe infection [51, 52]. The natural ligand of TLR10 has not yet been identified.
TLRs, their cellular location, ligand recognitions, and adaptor usage.
Bacteria: CpG DNA Viruses: CpG DNA Protozoa: CpG DNA, haemozoin
Chromatin IgG complex, HMGB
MyD88
TLRs also recognize a wide variety of endogenous ligands released from damaged tissues or cells killed during different cancer treatments (Table 1). These endogenous ligands are called DAMPs because they are released following tissue injury and cell death and serve as alarmins to trigger TLR activation, thereby providing an early warning signal to the immune system. DAMPs can be cellular components or stress-induced gene products, including extracellular matrix components, extracellular proteins, intracellular proteins, and nucleic acids [53, 54]. TLR2 and TLR4 recognize more DAMPs than other TLRs. TLR2 recognizes heat shock proteins (HSPs), Gp96 biglycan, hyaluronic acid, hyaluronan, HMGB1, versican, and monosodium urate crystal [55–63]. TLR4 senses HSPs, Gp96, HMGB1, oxidized phospholipids, heparin sulfate, fibrinogen, fibronectin, tenascin-C, β-defensin 2, hyaluronic acid, and hyaluronan [56, 61–71]. TLR3, TLR7, and TLR8 are activated by host RNA, and TLR9 is activated by host DNA from necrotic cells under special conditions, such as the formation of HMGB1, LL37, or immunoglobulin complex to facilitate ligand interaction with TLR [72–75].
3. TLR Signaling
In general, when the extracellular domain of TLR is bound by its ligand, two TLR monomers bridge to form a dimer. The TLR dimer then recruits adaptor proteins from the MyD88 family to initiate downstream signaling pathways (Table 1 and Figure 1). The MyD88 adaptor protein family contains five members: MyD88, TRIF/TICAM-1, TIRAP/Mal, TIRP/TRAM, and SRAM [76, 77]. All TLRs except TLR3 signal through a MyD88 dependent pathway, in which a MyD88/IRAK1/IRAK4/TRAF6 complex activates TAK1, which leads to the activation of transcription factors, including NF-κB and AP-1 [78–80]. TLR3 and TLR4 utilize a MyD88-independent pathway, recruiting TRIF to activate IRF3/7 and NF-κB. IRF3/7 activation involves TBK1-IKKε/IKKi complex; NF-κB and AP-1 activation involves TRAF6 and RIP [81–83].
TLR and the related TNFR and IL-1R signaling pathways. TLRs utilize a MYD88 dependent pathway (black line) and a TRIF dependent pathway (blue line) to activate NF-κB, AP-1, and IRF3, leading to the production of inflammatory cytokines and type I interferons. IL-1R uses the same set of signaling molecules, and TNFR utilizes the same signaling pathway as TLRs. TLR, toll-like receptor; IL-1R, interleukin-1 receptor; TNFR, tumor necrosis factor receptor; LPS, lipopolysaccharide; TRADD, TNFRSF1A associated via death domain; TIRAP, TIR domain containing adaptor protein; RIP, receptor interacting serine/threonine kinase; IRAK, interleukin-1 receptor associated kinase; TRAF2, TNF receptor associated factor 2; TRAF3, TNF receptor associated factor 3; TRAF6, TNF receptor associated factor 6; TAK1, TGF-beta activated kinase 1; MAPK, mitogen-activated protein kinase 1; IKK, I-kappa B kinase; IκB, NFKB inhibitor; Tab2, TGF-beta activated kinase 1 binding protein 2; TBK1, TANK-binding kinase 1; MYD88, myeloid differentiation primary response 88; TRIF, TIR domain containing adapter-inducing interferon-β; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; AP-1, activator protein 1; IRF3, interferon regulatory factor 3.
IL-1β and TNF-α are potent proinflammatory cytokines. TLR agonists and these two cytokines are major mediators of inflammation in the tumor microenvironment [6, 7]. As shown in Figure 1, the IL-1 receptor (IL-1R) utilizes the same signal transduction pathway as that utilized by TLRs: the sequential recruitment of MyD88, IRAK, and TRAF6 to form a complex and TAK activation leading to NF-κB activation. NF-κB activation downstream of the TNF-α receptor (TNFR) is mediated by TRADD, RIP, and TRAF2. The molecular components involved in TLR/IL-1R and TNFR signaling pathways only partially overlap; nevertheless, the regulation of these pathways is similar and involves the recruitment of adaptor molecules and ubiquitination-mediated regulation of protein expression and interaction.
4. Regulation of TLR Signaling
Ubiquitination regulates TLR signaling, leading to NF-κB activation [28, 84]. Ubiquitination is an enzymatic cascade involving three kinds of enzyme: a ubiquitin-activating enzyme (E1), a ubiquitin-conjugating enzyme (E2), and a ubiquitin-protein ligase (E3). Reactions occur with a single ubiquitin (monoubiquitination) or a chain of ubiquitins (polyubiquitination) conjugated to substrates. The specific ubiquitination of signaling molecules is mediated by E3 ligases (E3s) and counteracted by deubiquitinases (DUBs) [85–89]. There are approximately 600 E3s and 100 DUBs encoded in the human genome. E3s are characterized by distinct domains and can be divided into three groups: HECT, RING, and F-box. DUBs comprise five families: ovarian tumor proteases, ubiquitin-specific proteases (USPs), ubiquitin C-terminal hydrolases, Josephines, and JAB1/MPN/MOV34 metalloenzymes [86–89]. Seven internal lysine residues (K6, K11, K27, K29, K33, K48, and K63) and an N-terminal methionine (M1) residue in ubiquitin can be employed to generate eight structurally and functionally different ubiquitin chains. The type of chain depends on which lysine or M1 residue within a target protein/ubiquitin is attached to the C-terminal glycine of the incoming ubiquitin. K48 ubiquitination is involved in protein degradation via a ubiquitin-proteasome dependent pathway and K63 ubiquitination has been linked to protein-protein interaction for signal transduction [85–89]. Depending on the type of ubiquitination and target protein, E3 ubiquitin-protein ligases and DUBs can serve as positive or negative regulators of NF-κB activation following TLR activation.
Tables 2 and 3 list some E3 ubiquitin-protein ligases and DUBs that function as negative regulators of TLR signaling. For example, K48 ubiquitination promotes ubiquitin-proteasome degradation of IκB by the SCFβTrCP-E3 complex and subsequent NF-κB activation [90, 91]. NF-κB signaling is negatively regulated by USP11 or USP15-mediated removal of K48-linked ubiquitin chains from IκBα [92, 93]. Triad3A/RNF216 and SOCS1 regulate K48 ubiquitination and proteasomal degradation of TIRAP [94, 95]. SOCS1, COMMD1, and PDLIM2 catalyze K48-linked polyubiquitination and facilitate proteasomal degradation of p65/RelA [96–100]. The K63-linked ubiquitin chain in RIP, TRAF, and NEMO provides binding platforms for TAK-TAB and IKK activating complexes, leading to NF-κB activation. The DUBs, A20, CYLD, USP2, USP4, USP7, USP10, USP18, USP21, and USP25 terminate NF-κB signaling by removing K63-linked ubiquitin chains from signaling molecules [101–123]. Furthermore, A20, CYLD, and USP25 remove K63-linked ubiquitin chains from TRAF2, TRAF3, and TRAF6. These chains serve as docking platforms for downstream effectors, thereby preventing TRAF2, TRAF3, and TRAF6 from associating with their interaction partners [101, 106, 108, 109, 112, 119–121].
Negative regulators of TLR signaling involved in ubiquitination.
E3 ligase or adapter of E3 ligase complex
Target molecules
Ubiquitin-mediated modifications
Biological function
A20
RIP1, Ubc13
K48
Proteolytic degradation
Triad3A/RNF216
TLR3, TLR4, TLR5, TLR9, TIRAP, TRIP, RIP1
K48
Proteolytic degradation
SOCS1
TIRAP, IRAK, p65/RelA
K48
Proteolytic degradation
PDLIM2
P65/RelA
K48
Proteolytic degradation
COMMD1
P65/RelA
K48
Proteolytic degradation
TRIM27
IKKα, IKKβ
K48
Proteolytic degradation
TRIM38
TRAF6, TRIF, TAB2/3
K48
Proteolytic degradation
Negative regulators of TLR signaling involved in deubiquitination.
dUb
Target molecules
Ubiquitin-mediated modifications
Biological function
A20
RIP1, RIP2, TRAF2, TRAF6, MALT1, NEMO
K63
Signaling termination
CYLD
MyD88, TRAF2, TRAF6, TRAF7, RIP1, NEMO
K63
Signaling termination
USP2α
TRAF6
K63
Signaling termination
USP4
TRAF2, TRAF6, TAK1
K63
Signaling termination
USP7
TRAF6, NEMO
K63
Signaling termination
USP10
TRAF6, NEMO
K63/M1
Signaling termination
USP11
IκBα
K48
Proteolytic degradation
USP15
IκBα
K48
Proteolytic degradation
USP18
TAK1, NEMO
K63
Signaling termination
USP21
RIP1
K63
Signaling termination
USP25
TRAF2, TRAF3, TRAF5, TRAF6
K63/K48
Signaling termination/proteolytic degradation
5. TLR-Activated Inflammatory Responses and Tumor Progression
Human TLRs are expressed in various immune cells, including dendritic cells, macrophages, monocytes, natural killer cells, B cells, and T cells. In addition, TLRs are often expressed in tumor cells. Tumors, including lung, breast, liver, colorectal, prostate, pancreatic, melanoma, glioma, and esophageal cancers, have elevated TLR expression [124–128] (Table 4). TLRs can be activated in cells by PAMPs of carcinogenic microbes. The best known microbe-related cancers in humans are cervical cancer and oral cancer caused by the human papilloma viruses [129], gastric cancers caused by Helicobacter pylori [130], and hepatic cancers caused by hepatitis B and C viruses [131]. In addition, TLRs in tumor cells can be activated by DAMPs, such as HMGB1, S100, and HSPs, released from dying cells following chemotherapy or radiotherapy [132].
TLR expression profile.
Type of TLR
Immune cells
Tumor cells
TLR1
cDCs, eosinophils, monocytes, neutrophils, NK cells, pDCs, B cells
Myeloma cells
TLR2
cDCs, monocytes, neutrophils, NK cells, B cells, T cells
Eosinophils, monocytes, neutrophils, pDCs, B cells, T cells, Tregs
CRC
HCC, hepatocellular carcinoma; CRC, colorectal carcinoma; NHSCC, head and neck squamous cell carcinoma.
TLR activation increases transcription due to the activation of different transcription factors, including NF-κB, AP-1, and IRFs (Figure 1). NF-κB activates the transcription of multiple proinflammatory genes and is a key mediator of acute and chronic inflammatory responses [2–4, 8]. The genes of proinflammatory cytokines TNF-α and IL-1β are targets of NF-κB, and these cytokines can activate NF-κB signaling as effectively as TLR ligands. TNF-α and IL-1β are released into the tumor environment when TLRs are activated in tumor cells. This in turn activates NF-κB, resulting in sustained inflammatory cellular responses and chronic inflammation in the tumor microenvironment [6, 7]. In addition, NF-κB also controls the expression of genes involved in cell growth, proliferation, antiapoptosis, angiogenesis, tissue invasion, and metastasis. Typically, NF-κB controls cell growth and proliferation by increasing c-myc and cyclin D1, cyclin D2, cyclin D3, cyclin E, and CDK2, all of which regulate cell cycle progression. It also promotes growth by producing growth factors, including IL-2, IL-6, GM-CSF, and CD40L [133–138]. NF-κB inhibits apoptosis by regulating the antiapoptosis proteins cIAPs, c-FLP, and members of the Bcl-2 family [139]. NF-κB activation increases angiogenesis in tumors. Tumor cell invasion and metastasis are promoted by the upregulation of angiogenic factors, such as vascular endothelial growth factor; metastasis proteins, such as matrix metalloproteinases, urokinase-type plasminogen activator, MCP-1, MIP-1, and cathepsin B; and chemokines, such as IL-8 and CXCL1 in the tumor microenvironment. In addition, the expression of adhesion molecules, such as ICAM-1 and E-selection, is increased in tumor cells [9–11]. Consequently, TLR-activated inflammatory responses promote all stages of tumor progression from tumorigenesis to invasion and metastasis.
Consistent with this, many studies have demonstrated that TLR drives tumor progression. In animal models of HCC and head and neck carcinoma, TLR2 expression in tumor cells correlates positively with tumor progression [140–142]. TLR2 activation in host nontumor cells also has protumor effects. TLR2 depletion in the host cells of mice was reported to reduce the progression of breast, gastric, and intestinal tumors [143, 144]. The proposed mechanism involved TLR2-derived proinflammatory responses [140]. Similarly, protumor functions were observed following TLR4 activation in tumor cells and nontumor host cells. TLR4 activation in tumor cells promoted the growth of breast, lung, head and neck, and liver tumors in animal models [140, 145–149]. TLR4 activation in nontumor host cells increased the development of colitis-associated colorectal tumors and diethylnitrosamine-induced liver cancer in animal models [150, 151]. In addition, TLR5, TLR7, and TLR9 activation promoted tumor growth in different animal models of cancer [152–155]. The promotion of tumor development by TLRs has been supported by clinical data. TLR3 expression in tumor cells has been associated with poor clinical outcome in patients with prostate carcinoma [156]. TLR4 expression in breast and colorectal tumors has also been associated with a poor clinical outcome [157–159]. Strong TLR7 expression was associated with poor prognosis in patients with non-small cell lung cancer and predicted chemotherapy resistance in these patients [160]. Similarly, several studies have revealed an association between TLR9 overexpression in tumor cells and poor prognosis in patients with prostate carcinoma and glioblastoma. TLR9 overexpression has also been associated with an increased tumor grade in breast and ovarian cancers [156, 161, 162].
In contrast to these protumor effects, some studies have shown antitumor effects of TLR activation. TLR signaling elicited antitumor responses in the immune cells of tumor-bearing hosts to facilitate eradication of tumor cells. These results are not discussed in detail here but have been extensively reviewed elsewhere [163–165].
6. TLR Activation Enhances Stemness in Cancer Cells
CSCs are a small population of cancer cells found within tumors with high stemness. They are considered to be the cells of origin for tumor initiation and key drivers of malignancy. To achieve this, CSCs exhibit four main properties: (1) capacity to drive neoplastic proliferation and initiate tumors; (2) unlimited capacity for self-renewal; (3) potential to generate more differentiated progeny for heterogeneous cancer cell lineages, and (4) increased resistance to radiation and chemotherapy [12–16]. CSCs can evolve from normal stem cells, which have a long lifespan and are prone to accumulating mutations. Alternatively, CSCs can arise from restricted progenitor or differentiated cancer cells by genetic or epigenetic alterations that activate self-renewal mechanisms and promote stemness [13–16]. CSCs are usually distinguished from other cancer cells by the expression of specific surface markers, including CD133, CD44, CD24, and ALDH. Tumor forming capability can be examined in vitro by analyzing sphere formation in component-defined stem cell medium and low adherence plates. The ability to pump out drugs can be measured by side population analysis using flow cytometry. The tumorigenesis of sorted or enriched CSCs can be investigated using xenograft transplants [12–16].
CSCs play a key role in tumor development, and TLR activation promotes tumor progression; therefore, it is logical to propose that TLR signaling enhances stemness in cancer cells. Emerging evidence has demonstrated an association between NF-κB activation by TLR signaling and the expansion, invasion, and tumorigenesis of CSCs. For example, the TLR2-MyD88-NF-κB signaling pathway supports a proinflammatory microenvironment together with the expansion of the CD44+/MyD88+ epithelial ovarian cancer (EOC) stem cells by enhancing self-renewal, as shown by the upregulation of stemness-associated genes. CD44+/MyD88+ EOC stem cells are responsible for therapeutic resistance and recurrence in patients with EOC [166]. The stimulation of breast cancer cells with the TLR3 ligand poly(I:C) enhanced stemness in cancer cells through the simultaneous activation of β-catenin and NF-κB signaling pathways. TLR3 activation promoted the expression of stemness-associated genes, including OCT3/4, NANOG, and SOX2 [167]. Increased stem-like properties were associated with TLR4 expression in HCC, and TLR4 expression in HCC cells correlated significantly with enhanced invasion and migration to the splenic vein in nude mice. In clinical HCC tissues, high TLR4 expression correlated strongly with early recurrence and poor survival, which contributed to poor prognosis of HCC [168]. NF-κB suppression by IκBαSR in mammary epithelial cells impaired tumorigenesis and diminished tumor-associated macrophage and tumor neoangiogenesis in breast cancer. IκBαSR reduced the number of CD44+/CD24− stem cells and suppressed NANOG and SOX2 expression. These results indicate that the NF-κB pathway controls the tumorigenesis through regulation of stemness of breast cancer cells [169]. TLR4 activation may also activate TWIST1 and promote the formation of stem-like cancer cells in the mouse liver via a cooperation with nanog and STAT3 [170]. TLR9 expanded stem-like androgen-independent prostate cancer cells through NF-κB and STAT3 activation, which in turn upregulated the expression of stemness-associated genes, including NKX3.1, KLF-4, BMI-1, and COL1A1 [153].
7. Interplay between Inflammation and Stemness in Cancer Cells
NF-κB is activated by IL-1β and TNF-α, which are downstream effectors of TLR activation that also increase stemness in cancer cells. IL-1β and TGF-β cooperatively upregulate stemness-associated genes, including NESTIN, BMI-1, NOTCH-2, and LIF in glioma cells, thereby increasing invasiveness, drug resistance, and tumor growth in vivo [171]. IL-1β stimulated the expression of the stemness-associated genes NESTIN and BMI-1 in colon cancer cells, promoting sphere formation and increasing drug resistance. The expression of the EMT activator ZEB1 increased in IL-1β-induced sphere cells, suggesting a connection between EMT and IL-1β-induced CSC self-renewal [172]. In the study, TNF-α upregulated SLUG expression through canonical NF-κB/HIF1α signaling in human breast cancer cells. SLUG upregulation was reported to promote stemness in breast cancer cells, with increased CD44 and Jagged-1 expression, mammosphere growth, and extracellular matrix invasiveness [173]. These findings indicate that NF-κB-mediated inflammatory responses trigged by TLR, IL-1, and TNF-α signaling promote stemness in cancer cells.
In contrast, NF-κB-derived inflammatory responses are high in stemness-enriched cancer cells. In acute myelogenous leukemia, a subpopulation of CD34+ stemness-enriched cells was reported to exhibit high NF-κB activity, which was not seen in normal hematopoietic stem cells and leukemia cells. This study also identified a TNF-α autocrine pathway forming a NF-κB/TNF-α positive feedback loop that maintained NF-κB activation [174]. TRA-1-60-, CD151-, and CD166-positive stemness-enriched cancer cells purified from human prostate tumors exhibited increased NF-κB activity and inflammatory gene expression. These cells recapitulated parent tumor heterogeneity in serial xenograft experiments, indicating a hierarchy of human prostate cancer cell development and elevated NF-κB activity. This may represent a functional pathway of stemness-enriched cancer cells in human prostate cancer [22]. NF-κB activation is increased in glioblastoma CSCs. p65/RelA translocation into nuclei is higher in these cells than in non-CSCs [21]. A similar phenomenon was observed in ovarian cancer and breast CSCs. NF-κB activation and cytokine expression were elevated in ovarian CSCs. These stemness-enriched ovarian cancer cells were more resistant to anticancer drugs and were more metastatic than non-CSCs [175]. Stemness-enriched breast cancer cells have a CD44+/CD24− phenotype and higher NF-κB activity than CD44−/CD24+ breast cancer cells [176, 177].
These results indicate a bidirectional interplay between inflammation and stemness in cancer cells. The activation of NF-κB-mediated inflammation by extrinsic stimuli, such as TLR ligands, IL-1, and TNF-α, induces stemness in cancer cells. The expression of stemness-associated genes is regulated by NF-κB alone or in cooperation with other signaling pathways, such as STAT3 and NOTCH signaling pathways [18, 19, 21]. The regulation of EMT genes, such as SNAIL, SLUG, and TWIST1, promotes an EMT phenotype, which can initiate the metastasis and dedifferentiation of cancer cells into CSCs [18, 19, 173]. NANOG, SOX2, and POU5F1 are also regulated and are essential for maintaining the pluripotency of CSCs [169, 178–180]. Conversely, increased stemness enhances NF-κB activation in cancer cells. This may involve the intrinsic dysregulation of inflammatory signaling pathways in cancer cells.
8. Intrinsically Altered TLR Signaling Enhances Inflammation during the Enrichment of Stemness in Cancer Cells
This concept was illustrated by a recent report that demonstrated the downregulation of negative regulators of TLR signaling when stemness was enriched in head and neck squamous cell carcinoma (HNSCC) cells [181]. These downregulated negative regulators include COMMD1, SOCS1, and PDLIM2 control TLR signaling through ubiquitination and proteasomal degradation (Figure 1 and Table 2). COMMD1 was initially described as mouse U2af1-rs1 region 1 (Murr1) because it was first discovered in close proximity to U2af1-rs1 [182]. This protein lacks catalytic activities and was hypothesized to be an adaptor or scaffold protein with a role in protein-protein interactions [183, 184]. COMMD1 interacts with the p65/RelA subunit of NF-κB to promote ubiquitination and proteasomal degradation of the subunit [96, 97, 185]. SOCS1 acts as a ubiquitin ligase through its SOCS box domain leading to ubiquitination and proteasomal degradation of p65/RelA. Thus, SOCS1 restricts prolonged p65/RelA transactivation and terminates NF-κB-mediated inflammatory gene expression [98, 186]. In addition, TLR activation induces the expression of SOCS1, which is phosphorylated by Bruton’s tyrosine kinase, and then targets TIRAP for proteasomal degradation [95]. SOCS1 also interacts with IRAK to attenuate TLR signaling [187]. PDLIM2 functions as E3 ubiquitin ligase through its LIM domain and facilitates the polyubiquitination of p65/RelA. PDLIM2 binds p65/RelA through its PDZ domain, sequesters soluble p65/RelA within promyelocytic leukemia protein bodies, and subsequently assists the proteasomal degradation of p65 [181].
COMMD1 was downregulated by miR-205 during the enrichment of stemness in HNSCC cells. The reversal of COMMD1 downregulation correlated with the upregulation of the expression of NF-κB-controlled inflammatory genes, including PTGS2, IL8, IL-1A, CXCL2, IL-6, STAT5B, STAT3, CCL2, IL-1B, CD40, and IL-15. COMMD1 downregulation in cancer cells induced NF-κB activation and inflammatory responses in cancer cells and the tumor microenvironment. In addition, stemness was increased by reduced COMMD1 expression, as shown by increased sphere-forming capability and elevated expression of stemness-associated genes. COMMD1 downregulation promoted tumorigenicity and tumor growth and increased inflammation and stemness. Furthermore, COMMD1 downregulation was shown in head and neck, breast, lung, colon, gastric, and prostate cancers [181]. These findings indicate that altered TLR signaling drives a positive feedback interplay between inflammation and stemness in cancer cells.
9. Conclusion
Small CSC populations in tumors are key players in malignancy and reduce the success of cancer therapies. Most tumor tissue is removed by chemotherapy, radiotherapy, and surgery, but relapses occur if CSCs remain. Thus, understanding the underlying molecular mechanisms of CSC expansion is crucial for identifying new cancer therapies.
Chronic inflammation has been identified as a major factor for CSC expansion and tumor progression. As reviewed in this article, chronic inflammation can be initiated in the tumor microenvironment by an extrinsic cellular pathway in which TLRs are stimulated by PAMPs of carcinogenic microbes and DAMPs released from cancer cells killed during anticancer treatments. This activates NF-κB-mediated inflammation and increased stemness in cancer cells. Conversely, altered TLR signaling can lead to persistent activation of NF-kB-mediated inflammation during the enrichment of stemness in cancer cells.
This bidirectional positive feedback loop of inflammation and stemness in cancer cells can be a mechanism underlying malignancy and reduced treatment success. Blocking this loop by targeting TLR signaling may represent an effective strategy for inhibiting CSC expansion and tumor progression.
Competing Interests
The authors declare that they have no conflict of interests regarding the publication of this manuscript.
Acknowledgments
This work was supported in part by the National Health Research Institutes, Taiwan (Grant IM-105-PP-02) and Ministry of Science and Technology of Taiwan (Grants MOST104-3011-B010-001, MOST 104-2314-B-400-024, and MOST 105-2320-B-400-013-MY3).
ColottaF.AllavenaP.SicaA.GarlandaC.MantovaniA.Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability20093071073108110.1093/carcin/bgp1272-s2.0-67650151005HanahanD.WeinbergR. A.Hallmarks of cancer: the next generation2011144564667410.1016/j.cell.2011.02.0132-s2.0-79952284127ElinavE.NowarskiR.ThaissC. A.HuB.JinC.FlavellR. A.Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms2013131175977110.1038/nrc36112-s2.0-84888633713GrivennikovS. I.GretenF. R.KarinM.Immunity, inflammation, and cancer2010140688389910.1016/j.cell.2010.01.0252-s2.0-77950346282JunttilaM. R.de SauvageF. J.Influence of tumour micro-environment heterogeneity on therapeutic response2013501746734635410.1038/nature126262-s2.0-84884368877HoeselB.SchmidJ. A.The complexity of NF-κB signaling in inflammation and cancer2013121, article 8610.1186/1476-4598-12-862-s2.0-84880869807LawrenceT.The nuclear factor NF-kappaB pathway in inflammation200916a001651MantovaniA.AllavenaP.SicaA.BalkwillF.Cancer-related inflammation200845472034364441865091410.1038/nature072052-s2.0-4794909678118650914DiDonatoJ. A.MercurioF.KarinM.NF-κB and the link between inflammation and cancer2012246137940010.1111/j.1600-065x.2012.01099.xGaspariniC.FeldmannM.NF-κB as a target for modulating inflammatory responses201218355735574510.2174/1381612128035307632-s2.0-84870199424SarkarF. H.LiY.WangZ.KongD.NF-κB signaling pathway and its therapeutic implications in human diseases20082752933191885334110.1080/088301808022761792-s2.0-5394909076518853341ColakS.MedemaJ. P.Cancer stem cells—important players in tumor therapy resistance2014281214779479110.1111/febs.130232-s2.0-84915749487MageeJ. A.PiskounovaE.MorrisonS. J.Cancer stem cells: impact, heterogeneity, and uncertainty201221328329610.1016/j.ccr.2012.03.0032-s2.0-84858608410MertinsS. D.Cancer stem cells: a systems biology view of their role in prognosis and therapy201425435336710.1097/cad.00000000000000752-s2.0-84896397703ReyaT.MorrisonS. J.ClarkeM. F.WeissmanI. L.Stem cells, cancer, and cancer stem cells200141468591051111168995510.1038/351021672-s2.0-003549926711689955VisvaderJ. E.LindemanG. J.Cancer stem cells in solid tumours: accumulating evidence and unresolved questions200881075576810.1038/nrc24992-s2.0-52549087785KorkayaH.LiuS.WichaM. S.Regulation of cancer stem cells by cytokine networks: attacking cancer's inflammatory roots201117196125612910.1158/1078-0432.ccr-10-27432-s2.0-80053531658ShigdarS.LiY.BhattacharyaS.O'ConnorM.PuC.LinJ.WangT.XiangD.KongL.WeiM. Q.ZhuY.ZhouS.DuanW.Inflammation and cancer stem cells201434522712782394182810.1016/j.canlet.2013.07.0312-s2.0-8489670923423941828ZhouC.LiuJ.TangY.LiangX.Inflammation linking EMT and cancer stem cells20124811106810752276651010.1016/j.oraloncology.2012.06.0052-s2.0-8486788664122766510BirnieR.BryceS. D.RoomeC.DussuptV.DroopA.LangS. H.BerryP. A.HydeC. F.LewisJ. L.StowerM. J.MaitlandN. J.CollinsA. T.Gene expression profiling of human prostate cancer stem cells reveals a pro-inflammatory phenotype and the importance of extracellular matrix interactions200895, article R8310.1186/gb-2008-9-5-r832-s2.0-47149102561GarnerJ. M.FanM.YangC. H.DuZ.SimsM.DavidoffA. M.PfefferL. M.Constitutive activation of signal transducer and activator of transcription 3 (STAT3) and nuclear factor κB signaling in glioblastoma cancer stem cells regulates the notch pathway201328836261672617610.1074/jbc.m113.4779502-s2.0-84883682803RajasekharV. K.StuderL.GeraldW.SocciN. D.ScherH. I.Tumour-initiating stem-like cells in human prostate cancer exhibit increased NF-κB signalling20112, article 16210.1038/ncomms11592-s2.0-78751623400YamashinaT.BaghdadiM.YonedaA.KinoshitaI.SuzuS.Dosaka-AkitaH.JinushiM.Cancer stem-like cells derived from chemoresistant tumors have a unique capacity to prime tumorigenic myeloid cells20147410269827092463898010.1158/0008-5472.CAN-13-21692-s2.0-8490127724524638980ChenK.HuangJ.GongW.IribarrenP.DunlopN. M.WangJ. M.Toll-like receptors in inflammation, infection and cancer2007710127112851767314210.1016/j.intimp.2007.05.0162-s2.0-3454723117217673142HoebeK.JiangZ.GeorgelP.TabetaK.JanssenE.DuX.BeutlerB.TLR signaling pathways: opportunities for activation and blockade in pursuit of therapy200612324123413410.2174/1381612067787434662-s2.0-33750574752PiccininiA. M.MidwoodK. S.DAMPening inflammation by modulating TLR signalling201020102167239510.1155/2010/6723952-s2.0-77955383770BelvinM. P.AndersonK. V.A conserved signaling pathway: the Drosophila toll-dorsal pathway19961239341610.1146/annurev.cellbio.12.1.3932-s2.0-0029730738KawaiT.AkiraS.Signaling to NF-κB by Toll-like receptors2007131146046910.1016/j.molmed.2007.09.0022-s2.0-36049033394HashimotoC.HudsonK. L.AndersonK. V.The Toll gene of Drosophila, required for dorsal-ventral embryonic polarity, appears to encode a transmembrane protein198852226927910.1016/0092-8674(88)90516-82-s2.0-0024299087ChuangT.-H.UlevitchR. J.Identification of hTLR10: a novel human Toll-like receptor preferentially expressed in immune cells200115181-215716110.1016/s0167-4781(00)00289-x2-s2.0-0035911644RockF. L.HardimanG.TimansJ. C.KasteleinR. A.BazanJ. F.A family of human receptors structurally related to Drosophila Toll199895258859310.1073/pnas.95.2.5882-s2.0-0031905311TakedaK.AkiraS.TLR signaling pathways2004161391475175710.1016/j.smim.2003.10.0032-s2.0-074232486014751757AliprantisA. O.YangR.-B.MarkM. R.SuggettS.DevauxB.RadolfJ. D.KlimpelG. R.GodowskiP.ZychlinskyA.Cell activation and apoptosis by bacterial lipoproteins through toll-like receptor-21999285542873673910.1126/science.285.5428.7362-s2.0-0033618630CoelhoP. S.KleinA.TalvaniA.CoutinhoS. F.TakeuchiO.AkiraS.SilvaJ. S.CanizzaroH.GazzinelliR. T.TeixeiraM. M.Glycosylphosphatidylinositol-anchored mucin-like glycoproteins isolated from Trypanosoma cruzi trypomastigotes induce in vivo leukocyte recruitment dependent on MCP-1 production by IFN-gamma-primed-macrophages20027158378442-s2.0-0036587576JanewayC. A.Jr.MedzhitovR.Innate immune recognition2002201972161186160210.1146/annurev.immunol.20.083001.0843592-s2.0-003621284911861602MassariP.HennekeP.HoY.LatzE.GolenbockD. T.WetzlerL. M.Cutting edge: immune stimulation by neisserial porins is toll-like receptor 2 and MyD88 dependent200216841533153710.4049/jimmunol.168.4.15332-s2.0-0037083638MeansT. K.WangS.LienE.YoshimuraA.GolenbockD. T.FentonM. J.Human Toll-like receptors mediate cellular activation by Mycobacterium tuberculosis1999163739203927104909932-s2.0-003321512310490993SchwandnerR.DziarskiR.WescheH.RotheM.KirschningC. J.Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2199927425174061740910.1074/jbc.274.25.174062-s2.0-0033580949UnderhillD. M.OzinskyA.HajjarA. M.StevensA.WilsonC. B.BassettiM.AderemA.The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens199940167558118151054810910.1038/446052-s2.0-003359274810548109OzinskyA.UnderhillD. M.FontenotJ. D.HajjarA. M.SmithK. D.WilsonC. B.SchroederL.AderemA.The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between Toll-like receptors2000972513766137711109574010.1073/pnas.2504764972-s2.0-003461029111095740TakeuchiO.KawaiT.MühlradtP. F.MorrM.RadolfJ. D.ZychlinskyA.TakedaK.AkiraS.Discrimination of bacterial lipoproteins by toll-like receptor 6200113793394010.1093/intimm/13.7.9332-s2.0-0034922923TakeuchiO.SatoS.HoriuchiT.HoshinoK.TakedaK.DongZ.ModlinR. L.AkiraS.Cutting edge: role of toll-like receptor 1 in mediating immune response to microbial lipoproteins20021691101410.4049/jimmunol.169.1.102-s2.0-0036644042AlexopoulouL.HoltA. C.MedzhitovR.FlavellR. A.Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 32001413685773273810.1038/350995602-s2.0-0035909372MedzhitovR.Preston-HurlburtP.JanewayC. A.Jr.A human homologue of the Drosophila toll protein signals activation of adaptive immunity1997388664039439710.1038/411312-s2.0-0030831210PoltorakA.HeX.SmirnovaI.LiuM.-Y.Van HuffelC.DuX.BirdwellD.AlejosE.SilvaM.GalanosC.FreudenbergM.Ricciardi-CastagnoliP.LaytonB.BeutlerB.Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene199828253962085208810.1126/science.282.5396.20852-s2.0-0032509295HayashiF.SmithK. D.OzinskyA.HawnT. R.YiE. C.GoodlettD. R.EngJ. K.AkiraS.UnderhillD. M.AderemA.The innate immune response to bacterial flagellin is mediated by Toll-like receptor 520014106832109911031132367310.1038/350741062-s2.0-003595354311323673ChuangT.-H.UlevitchR. J.Cloning and characterization of a sub-family of human toll-like receptors: hTLR7, hTLR8 and hTLR920001133723782-s2.0-0034457684DuX.PoltorakA.WeiY.BeutlerB.Three novel mammalian toll-like receptors: gene structure, expression, and evolution20001133623712-s2.0-0034456693DieboldS. S.KaishoT.HemmiH.AkiraS.Reis e SousaC.Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA200430356631529153110.1126/science.10936162-s2.0-1542317550HeilF.HemmiH.HochreinH.AmpenbergerF.KirschningC.AkiraS.LipfordG.WagnerH.BauerS.Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8200430356631526152910.1126/science.10936202-s2.0-1542317578KriegA. M.The role of CpG motifs in innate immunity200012135431067940610.1016/S0952-7915(99)00048-52-s2.0-003398007310679406KriegA. M.YiA.-K.MatsonS.WaldschmidtT. J.BishopG. A.TeasdaleR.KoretzkyG. A.KlinmanD. M.CpG motifs in bacterial DNA trigger direct B-cell activation19953746522546549770038010.1038/374546a02-s2.0-00289311027700380MatzingerP.The danger model: a renewed sense of self2002296556630130510.1126/science.10710592-s2.0-0037066427SeongS.-Y.MatzingerP.Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses20044646947810.1038/nri13722-s2.0-2942627626CurtinJ. F.LiuN.CandolfiM.XiongW.AssiH.YagizK.EdwardsM. R.MichelsenK. S.KroegerK. M.LiuC.MuhammadA. K. M. G.ClarkM. C.ArditiM.Comin-AnduixB.RibasA.LowensteinP. R.CastroM. G.HMGB1 mediates endogenous TLR2 activation and brain tumor regression200961, article e102-s2.0-70349982431JiangD.LiangJ.FanJ.YuS.ChenS.LuoY.PrestwichG. D.MascarenhasM. M.GargH. G.QuinnD. A.HomerR. J.GoldsteinD. R.BucalaR.LeeP. J.MedzhitovR.NobleP. W.Regulation of lung injury and repair by Toll-like receptors and hyaluronan20051111117311791624465110.1038/nm13152-s2.0-3074446230016244651KimS.TakahashiH.LinW.-W.DescarguesP.GrivennikovS.KimY.LuoJ.-L.KarinM.Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis200945772251021061912264110.1038/nature076232-s2.0-5814926934819122641Liu-BryanR.PritzkerK.FiresteinG. S.TerkeltaubR.TLR2 signaling in chondrocytes drives calcium pyrophosphate dihydrate and monosodium urate crystal-induced nitric oxide generation200517485016502310.4049/jimmunol.174.8.50162-s2.0-17144371314Liu-BryanR.ScottP.SydlaskeA.RoseD. M.TerkeltaubR.Innate immunity conferred by Toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation2005529293629461614271210.1002/art.212382-s2.0-2544445429516142712SchaeferL.BabelovaA.KissE.HausserH.-J.BaliovaM.KrzyzankovaM.MarscheG.YoungM. F.MihalikD.GötteM.MalleE.SchaeferR. M.GröneH.-J.The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages200511582223223310.1172/jci237552-s2.0-23644456849VabulasR. M.Ahmad-NejadP.da CostaC.MiethkeT.KirschningC. J.HäckerH.WagnerH.Endocytosed HSP60s use toll-like receptor 2 (TLR2) and TLR4 to activate the toll/interleukin-1 receptor signaling pathway in innate immune cells200127633313323133910.1074/jbc.m1032172002-s2.0-0035903158VabulasR. M.Ahmad-NejadP.GhoseS.KirschningC. J.IsselsR. D.WagnerH.HSP70 as endogenous stimulus of the Toll/interleukin-1 receptor signal pathway200227717151071511210.1074/jbc.m1112042002-s2.0-0037177833VabulasR. M.BraedelS.HilfN.Singh-JasujaH.HerterS.Ahmad-NejadP.KirschningC. J.RammenseeC. D. C. H.-G.WagnerH.SchildH.The endoplasmic reticulum-resident heat shock protein Gp96 activates dendritic cells via the toll-like receptor 2/4 pathway200227723208472085310.1074/jbc.m2004252002-s2.0-0037036369BiragynA.RuffiniP. A.LeiferC. A.KlyushnenkovaE.ShakhovA.ChertovO.ShirakawaA. K.FarberJ. M.SegalD. M.OppenheimJ. J.KwakL. W.Toll-like receptor 4-dependent activation of dendritic cells by β-defensin 2200229855951025102910.1126/science.10755652-s2.0-0036829687ImaiY.KubaK.NeelyG. G.Yaghubian-MalhamiR.PerkmannT.van LooG.ErmolaevaM.VeldhuizenR.LeungY. H. C.WangH.LiuH.SunY.PasparakisM.KopfM.MechC.BavariS.PeirisJ. S. M.SlutskyA. S.AkiraS.HultqvistM.HolmdahlR.NichollsJ.JiangC.BinderC. J.PenningerJ. M.Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury2008133223524910.1016/j.cell.2008.02.0432-s2.0-41949087380JohnsonG. B.BrunnG. J.KodairaY.PlattJ. L.Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by toll-like receptor 42002168105233523910.4049/jimmunol.168.10.52332-s2.0-0037094084MidwoodK.SacreS.PiccininiA. M.InglisJ.TrebaulA.ChanE.DrexlerS.SofatN.KashiwagiM.OrendG.BrennanF.FoxwellB.Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease20091577747801956161710.1038/nm.19872-s2.0-6765050273919561617OkamuraY.WatariM.JerudE. S.YoungD. W.IshizakaS. T.RoseJ.ChowJ. C.StraussJ. F.IIIThe extra domain A of fibronectin activates Toll-like receptor 4200127613102291023310.1074/jbc.m1000992002-s2.0-0035971217ParkJ. S.SvetkauskaiteD.HeQ.KimJ.-Y.StrassheimD.IshizakaA.AbrahamE.Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein200427997370737710.1074/jbc.m3067932002-s2.0-1542380035SmileyS. T.KingJ. A.HancockW. W.Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4200116752887289410.4049/jimmunol.167.5.28872-s2.0-0035451118TesarB. M.JiangD.LiangJ.PalmerS. M.NobleP. W.GoldsteinD. R.The role of hyaluronan degradation products as innate alloimmune agonists20066112622263510.1111/j.1600-6143.2006.01537.x2-s2.0-33750024480BarratF. J.MeekerT.GregorioJ.ChanJ. H.UematsuS.AkiraS.ChangB.DuramadO.CoffmanR. L.Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus200520281131113910.1084/jem.200509142-s2.0-26844467349KarikóK.NiH.CapodiciJ.LamphierM.WeissmanD.mRNA is an endogenous ligand for Toll-like receptor 3200427913125421255010.1074/jbc.m3101752002-s2.0-1842477469LeadbetterE. A.RifkinI. R.HohlbaumA. M.BeaudetteB. C.ShlomchikM. J.Marshak-RothsteinA.Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors200241668816036071194834210.1038/416603a2-s2.0-003706145311948342VollmerJ.TlukS.SchmitzC.HammS.JurkM.ForsbachA.AkiraS.KellyK. M.ReevesW. H.BauerS.KriegA. M.Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8200520211157515851633081610.1084/jem.200516962-s2.0-2854444970916330816O'NeillL. A. J.BowieA. G.The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling2007753533641745734310.1038/nri20792-s2.0-3424756651017457343O'NeillL. A. J.FitzgeraldK. A.BowieA. G.The Toll-IL-1 receptor adaptor family grows to five members20032462862891281009810.1016/S1471-4906(03)00115-72-s2.0-003750536212810098Ninomiya-TsujiJ.KishimotoK.HiyamaA.InoueJ.-I.CaoZ.MatsumotoK.The kinase TAK1 can activate the NIK-IκB as well as the MAP kinase cascade in the IL-1 signalling pathway1999398672425225610.1038/184652-s2.0-0033580466YamaguchiK.ShirakabeK.ShibuyaH.IrieK.OishiI.UenoN.TaniguchiT.NishidaE.MatsumotoK.Identification of a member of the MAPKKK family as a potential mediator of TGF-β signal transduction199527052442008201110.1126/science.270.5244.20082-s2.0-0029551805WangC.DengL.HongM.AkkarajuG. R.InoueJ.-I.ChenZ. J.TAK1 is a ubiquitin-dependent kinase of MKK and IKK200141268443463511146016710.1038/350855972-s2.0-003591327811460167DengL.WangC.SpencerE.YangL.BraunA.YouJ.SlaughterC.PickartC.ChenZ. J.Activation of the Iκb kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain2000103235136110.1016/s0092-8674(00)00126-42-s2.0-0034644474FitzgeraldK. A.RoweD. C.BarnesB. J.CaffreyD. R.VisintinA.LatzE.MonksB.PithaP. M.GolenbockD. T.LPS-TLR4 signaling to IRF-3/7 and NF-κB involves the toll adapters TRAM and TRIF200319871043105510.1084/jem.200310232-s2.0-0141959224MeylanE.BurnsK.HofmannK.BlancheteauV.MartinonF.KelliherM.TschoppJ.RIP1 is an essential mediator of Toll-like receptor 3-induced NF-kappa B activation2004555035072-s2.0-2442642691ChenZ. J.Ubiquitin signalling in the NF-κB pathway20057875876510.1038/ncb0805-7582-s2.0-23144449789Bibeau-PoirierA.ServantM. J.Roles of ubiquitination in pattern-recognition receptors and type I interferon receptor signaling20084333593671870789810.1016/j.cyto.2008.07.0122-s2.0-5134908310118707898ClagueM. J.HerideC.UrbéS.The demographics of the ubiquitin system20152574174262590690910.1016/j.tcb.2015.03.0022-s2.0-8493764013525906909HarhajE. W.DixitV. M.Regulation of NF-κB by deubiquitinases2012246110712410.1111/j.1600-065x.2012.01100.x2-s2.0-84858725584PopovicD.VucicD.DikicI.Ubiquitination in disease pathogenesis and treatment201420111242125310.1038/nm.37392-s2.0-84922393807ZinngrebeJ.MontinaroA.PeltzerN.WalczakH.Ubiquitin in the immune system2014151284510.1002/embr.2013380252-s2.0-84894559172SchererD. C.BrockmanJ. A.ChenZ.ManiatisT.BallardD. W.Signal-induced degradation of I kappa B alpha requires site-specific ubiquitination19959224112591126310.1073/pnas.92.24.112592-s2.0-0028972488TanP.FuchsS. Y.ChenA.WuK.GomezC.RonaiZ.PanZ.-Q.Recruitment of a ROC1-CUL1 ubiquitin ligase by Skp1 and HOS to catalyze the ubiquitination of IκBα19993452753310.1016/s1097-2765(00)80481-52-s2.0-0033120593SchweitzerK.BozkoP. M.DubielW.NaumannM.CSN controls NF-κB by deubiquitinylation of IκBα200726615321541YamaguchiT.KimuraJ.MikiY.YoshidaK.The deubiquitinating enzyme USP11 controls an IkappaB kinase alpha (IKKalpha)-p53 signaling pathway in response to tumor necrosis factor alpha (TNFalpha)2007282473394333948FearnsC.PanQ.MathisonJ. C.ChuangT.-H.Triad3A regulates ubiquitination and proteasomal degradation of RIP1 following disruption of Hsp90 binding200628145345923460010.1074/jbc.m6040192002-s2.0-33845926057MansellA.SmithR.DoyleS. L.GrayP.FennerJ. E.CrackP. J.NicholsonS. E.HiltonD. J.O'NeillL. A. J.HertzogP. J.Suppressor of cytokine signaling 1 negatively regulates Toll-like receptor signaling by mediating Mal degradation20067214815510.1038/ni12992-s2.0-31344467156BursteinE.HobergJ. E.WilkinsonA. S.RumbleJ. M.CsomosR. A.KomarckC. M.MaineG. N.WilkinsonJ. C.MayoM. W.DuckettC. S.COMMD proteins, a novel family of structural and functional homologs of MURR1200528023222222223210.1074/jbc.m5019282002-s2.0-20444470299MaineG. N.MaoX.KomarckC. M.BursteinE.COMMD1 promotes the ubiquitination of NF-κB subunits through a cullin-containing ubiquitin ligase200726243644710.1038/sj.emboj.76014892-s2.0-33846475712RyoA.SuizuF.YoshidaY.PerremK.LiouY.-C.WulfG.RottapelR.YamaokaS.LuK. P.Regulation of NF-κB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA20031261413142610.1016/s1097-2765(03)00490-82-s2.0-0347955360TanakaT.GrusbyM. J.KaishoT.PDLIM2-mediated termination of transcription factor NF-κB activation by intranuclear sequestration and degradation of the p65 subunit20078658459110.1038/ni14642-s2.0-34249066486TanakaT.ShibazakiA.OnoR.KaishoT.HSP70 mediates degradation of the p65 subunit of nuclear factor κb to inhibit inflammatory signaling20147356ra11910.1126/scisignal.20055332-s2.0-84919389255BooneD. L.TurerE. E.LeeE. G.AhmadR. C.WheelerM. T.TsuiC.HurleyP.ChienM.ChaiS.HitotsumatsuO.McNallyE.PickartC.MaA.The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses200451010521060DaubeufS.SinghD.TanY.LiuH.FederoffH. J.BowersW. J.TolbaK.HSV ICP0 recruits USP7 to modulate TLR-mediated innate response2009113143264327510.1182/blood-2008-07-1682032-s2.0-65349175161FanY.-H.YuY.MaoR.-F.TanX.-J.XuG.-F.ZhangH.LuX.-B.FuS.-B.YangJ.USP4 targets TAK1 to downregulate TNFα-induced NF-κB activation201118101547156010.1038/cdd.2011.112-s2.0-80052691620HeX.LiY.LiC.LiuL.-J.ZhangX.-D.LiuY.ShuH.-B.USP2a negatively regulates IL-1β- and virus-induced NF-κB activation by deubiquitinating TRAF6201351394710.1093/jmcb/mjs0242-s2.0-84874332545HitotsumatsuO.AhmadR.-C.TavaresR.WangM.PhilpottD.TurerE. E.LeeB. L.ShiffinN.AdvinculaR.MalynnB. A.WertsC.MaA.The ubiquitin-editing enzyme A20 restricts nucleotide-binding oligomerization domain containing 2-triggered signals200828338139010.1016/j.immuni.2008.02.0022-s2.0-40449136493JonoH.LimJ. H.ChenL.-F.XuH.TrompoukiE.PanZ. K.MosialosG.LiJ.-D.NF-κB is essential for induction of CYLD, the negative regulator of NF-κB: evidence for a novel inducible autoregulatory feedback pathway200427935361713617410.1074/jbc.m4066382002-s2.0-4344561190LeeB.-C.MiyataM.LimJ. H.LiJ.-D.Deubiquitinase CYLD acts as a negative regulator for bacterium NTHi-induced inflammation by suppressing K63-linked ubiquitination of MyD8820161132E165E17110.1073/pnas.15186151132-s2.0-84954553782LiL.SoetandyoN.WangQ.YeY.The zinc finger protein A20 targets TRAF2 to the lysosomes for degradation20091793234635310.1016/j.bbamcr.2008.09.0132-s2.0-58749100827LinD.ZhangM.ZhangM.-X.RenY.ZhaoQ.JinJ.PanZ.WuM.ShuH.-B.DongC.ZhongB.Induction of USP25 by viral infection promotes innate antiviral responses by mediating the stabilization of TRAF3 and TRAF6201511236113241132910.1073/pnas.15099681122-s2.0-84941248283LiuX.LiH.ZhongB.BlonskaM.GorjestaniS.YanM.TianQ.ZhangD.-E.LinX.DongC.Usp18 inhibits NF-κb and NFAT activation during Th17 differentiation by deubiquitinating the TAK1-TAB1 complex201321081575159010.1084/jem.201223272-s2.0-84884234601MauroC.PacificoF.LavorgnaA.MelloneS.IannettiA.AcquavivaR.FormisanoS.VitoP.LeonardiA.ABIN-1 binds to NEMO/IKKγ and co-operates with A20 in inhibiting NF-κB200628127184821848810.1074/jbc.m6015022002-s2.0-33745856562TrompoukiE.HatzivassillouE.TsichritzisT.FarmerH.AshworthA.MosialosG.CYLD is a deubiquitinating enzyme that negatively regulates NF-κB activation by TNFR family members2003424695079379610.1038/nature018032-s2.0-0042467558WangW.HuangX.XinH.-B.FuM.XueA.WuZ.-H.TRAF family member-associated NF-κB activator (TANK) inhibits genotoxic nuclear factor κB activation by facilitating deubiquitinase USP10-dependent deubiquitination of TRAF6 ligase201529021133721338510.1074/jbc.m115.6437672-s2.0-84930010074WartzI. E.O'RourkeK. M.ZhouH.EbyM.AravindL.SeshagiriS.WuP.WiesmannC.BakerR.BooneD. L.MaA.KooninE. V.DixitV. M.De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signalling2004430700069469910.1038/nature027942-s2.0-3943054838WrightA.ReileyW. W.ChangM.JinW.LeeA. J.ZhangM.SunS.-C.Regulation of early wave of germ cell apoptosis and spermatogenesis by deubiquitinating enzyme CYLD200713570571610.1016/j.devcel.2007.09.0072-s2.0-35548974703XiaoN.LiH.LuoJ.WangR.ChenH.ChenJ.WangP.Ubiquitin-specific protease 4 (USP4) targets TRAF2 and TRAF6 for deubiquitination and inhibits TNFα-induced cancer cell migration2012441397998610.1042/bj201113582-s2.0-84862907678XuG.TanX.WangH.SunW.ShiY.BurlingameS.GuX.CaoG.ZhangT.QinJ.YangJ.Ubiquitin-specific peptidase 21 inhibits tumor necrosis factor α-induced nuclear factor κB activation via binding to and deubiquitinating receptor-interacting protein 12010285296997810.1074/jbc.m109.0426892-s2.0-74049114641YangZ.XianH.HuJ.TianS.QinY.WangR.-F.CuiJ.USP18 negatively regulates NF-κB signaling by targeting TAK1 and NEMO for deubiquitination through distinct mechanisms20155, article 1273810.1038/srep127382-s2.0-84938809839YoshidaH.JonoH.KaiH.LiJ.-D.The tumor suppressor cylindromatosis (CYLD) acts as a negative regulator for toll-like receptor 2 signaling via negative cross-talk with TRAF6 and TRAF7200528049411114112110.1074/jbc.m5095262002-s2.0-28844460239ZhongB.LiuX.WangX.ChangS. H.LiuX.WangA.ReynoldsJ. M.DongC.Negative regulation of IL-17-mediated signaling and inflammation by the ubiquitin-specific protease USP2520121311111011172304215010.1038/ni.24272-s2.0-8486772953923042150ZhongH.WangD.FangL.ZhangH.LuoR.ShangM.OuyangC.OuyangH.ChenH.XiaoS.Ubiquitin-specific proteases 25 negatively regulates virus-induced type I interferon signaling2013811e809762426052510.1371/journal.pone.00809762-s2.0-8489408790724260525ZhouF.ZhangX.van DamsH.Ten DijkesP.HuangH.ZhangL.Ubiquitin-specific protease 4 mitigates toll-like/interleukin-1 receptor signaling and regulates innate immune activation201228714110021101010.1074/jbc.m111.3281872-s2.0-84859507872NiuJ.ShiY.XueJ.MiaoR.HuangS.WangT.WuJ.FuM.WuZ.-H.USP10 inhibits genotoxic NF-κB activation by MCPIP1-facilitated deubiquitination of NEMO201332243206321910.1038/emboj.2013.2472-s2.0-84890568965González-ReyesS.MarínL.GonzálezL.GonzálezL. O.Del CasarJ. M.LamelasM. L.González-QuintanaJ. M.VizosoF. J.Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis201010, article 66510.1186/1471-2407-10-6652-s2.0-78649552269ParkH. D.LeeY.OhY. K.JungJ. G.ParkY. W.MyungK.KimK.-H.KohS. S.LimD.-S.Pancreatic adenocarcinoma upregulated factor promotes metastasis by regulating TLR/CXCR4 activation20113022012112080252710.1038/onc.2010.4012-s2.0-7865140734320802527SatoY.GotoY.NaritaN.HoonD. S. B.Cancer cells expressing toll-like receptors and the tumor microenvironment20092supplement 1S205S21410.1007/s12307-009-0022-y2-s2.0-70350664389SheyhidinI.NabiG.HasimA.ZhangR.-P.AiniwaerJ.MaH.WangH.Overexpression of TLR3, TLR4, TLR7 and TLR9 in esophageal squamous cell carcinoma20111732374537512199095710.3748/wjg.v17.i32.37452-s2.0-8005390865021990957TewariR.ChoudhuryS. R.GhoshS.MehtaV. S.SenE.Involvement of TNFα-induced TLR4–NF-κB and TLR4–HIF-1α feed-forward loops in the regulation of inflammatory responses in glioma2012901678010.1007/s00109-011-0807-62-s2.0-84857363522MuñozN.CastellsaguéX.de GonzálezA. B.GissmannL.Chapter 1: HPV in the etiology of human cancer200624supplement 3S1S1010.1016/j.vaccine.2006.05.1152-s2.0-33747881589ParsonnetJ.FriedmanG. D.VandersteenD. P.ChangY.VogelmanJ. H.OrentreichN.SibleyR. K.Helicobacter pylori infection and the risk of gastric carcinoma1991325161127113110.1056/nejm1991101732516032-s2.0-0025945933El-SeragH. B.Epidemiology of viral hepatitis and hepatocellular carcinoma201214261264.e11273.e110.1053/j.gastro.2011.12.0612-s2.0-84860287080SrikrishnaG.FreezeH. H.Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer20091176156281956840710.1593/neo.092842-s2.0-6765048288319568407DuyaoM. P.BucklerA. J.SonensheinG. E.Interaction of an NF-κB-like factor with a site upstream of the c-myc promoter1990871247274731219130010.1073/pnas.87.12.47272-s2.0-00253025522191300GuttridgeD. C.AlbaneseC.ReutherJ. Y.PestellR. G.BaldwinA. S.Jr.NF-κB controls cell growth and differentiation through transcriptional regulation of cyclin D11999198578557991040976510.1128/MCB.19.8.57852-s2.0-003258818610409765LibermannT. A.BaltimoreD.Activation of interleukin-6 gene expression through the NF-κB transcription factor199010523272334218303110.1128/MCB.10.5.23272-s2.0-00253438952183031SchreckR.BaeuerleP. A.NF-κB as inducible transcriptional activator of the granulocyte-macrophage colony-stimulating factor gene199010312811286240656810.1128/MCB.10.3.12812-s2.0-00251394632406568SchubertL. A.CronR. Q.ClearyA. M.BrunnerM.SongA.LuL.-S.JullienP.KrenskyA. M.LewisD. B.A T cell-specific enhancer of the human CD40 ligand gene20022779738673951175188810.1074/jbc.M1103502002-s2.0-003651055211751888SerflingE.BarthelmasR.PfeufferI.SchenkB.ZariusS.SwobodaR.MercurioF.KarinM.Ubiquitous and lymphocyte-specific factors are involved in the induction of the mouse interleukin 2 gene in T lymphocytes19898246547325420172-s2.0-00243302652542017GhoshS.KarinM.Missing pieces in the NF-κB puzzle20021092S81S961198315510.1016/S0092-8674(02)00703-12-s2.0-003623445911983155FarneboL.ShahangianA.LeeY.ShinJ. H.ScheerenF. A.SunwooJ. B.Targeting Toll-like receptor 2 inhibits growth of head and neck squamous cell carcinoma20156129897990710.18632/oncotarget.33932-s2.0-84929583365HuangB.ZhaoJ.ShenS.LiH.HeK.-L.ShenG.-X.MayerL.UnkelessJ.LiD.YuanY.ZhangG.-M.XiongH.FengZ.-H.Listeria monocytogenes promotes tumor growth via tumor cell toll-like receptor 2 signaling2007679434643521748334810.1158/0008-5472.CAN-06-40672-s2.0-3424930816017483348ShiW.LihuiS.LiQ.SunL.LvJ.LiJ.ChengB.Suppression of toll-like receptor 2 expression inhibits the bioactivity of human hepatocellular carcinoma20143510962796372496496410.1007/s13277-014-2268-32-s2.0-8492239251224964964ScheerenF. A.KuoA. H.Van WeeleL. J.CaiS.GlykofridisI.SikandarS. S.ZabalaM.QianD.LamJ. S.JohnstonD.VolkmerJ. P.SahooD.Van De RijnM.DirbasF. M.SomloG.KaliskyT.RothenbergM. E.QuakeS. R.ClarkeM. F.A cell-intrinsic role for TLR2-MYD88 in intestinal and breast epithelia and oncogenesis20141612123812482536235110.1038/ncb30582-s2.0-8492528608925362351TyeH.KennedyC. L.NajdovskaM.McLeodL.McCormackW.HughesN.DevA.SievertW.OoiC. H.IshikawaT.-O.OshimaH.BhathalP. S.ParkerA. E.OshimaM.TanP.JenkinsB. J.STAT3-driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation201222446647810.1016/j.ccr.2012.08.0102-s2.0-84867605321HsiaoC.-C.ChenP.-H.ChengC.-I.TsaiM.-S.ChangC.-Y.LuS.-C.HsiehM.-C.LinY.-C.LeeP.-H.KaoY.-H.Toll-like receptor-4 is a target for suppression of proliferation and chemoresistance in HepG2 hepatoblastoma cells201536811441522627672510.1016/j.canlet.2015.08.0042-s2.0-8494074463226276725SzczepanskiM. J.CzystowskaM.SzajnikM.HarasymczukM.BoyiadzisM.Kruk-ZagajewskaA.SzyfterW.ZeromskiJ.WhitesideT. L.Triggering of toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack2009697310531131931856010.1158/0008-5472.CAN-08-38382-s2.0-6614914064419318560YangH.WangB.WangT.XuL.HeC.WenH.YanJ.SuH.ZhuX.Toll-like receptor 4 prompts human breast cancer cells invasiveness via lipopolysaccharide stimulation and is overexpressed in patients with lymph node metastasis2014910e1099802529905210.1371/journal.pone.01099802-s2.0-8490781601825299052YangH.ZhouH.FengP.ZhouX.WenH.XieX.ShenH.ZhuX.Reduced expression of Toll-like receptor 4 inhibits human breast cancer cells proliferation and inflammatory cytokines secretion2010291, article no. 922061897610.1186/1756-9966-29-922-s2.0-7795433627320618976HeW.LiuQ.WangL.ChenW.LiN.CaoX.TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance20074411285028591732895510.1016/j.molimm.2007.01.0222-s2.0-3394717988717328955DapitoD. H.MencinA.GwakG.-Y.PradereJ.-P.JangM.-K.MederackeI.CavigliaJ. M.KhiabanianH.AdeyemiA.BatallerR.LefkowitchJ. H.BowerM.FriedmanR.SartorR. B.RabadanR.SchwabeR. F.Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4201221450451610.1016/j.ccr.2012.02.0072-s2.0-84859812538FukataM.ChenA.VamadevanA. S.CohenJ.BreglioK.KrishnareddyS.HsuD.XuR.HarpazN.DannenbergA. J.SubbaramaiahK.CooperH. S.ItzkowitzS. H.AbreuM. T.Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors200713361869188110.1053/j.gastro.2007.09.0082-s2.0-36549082403Cherfils-ViciniJ.PlatonovaS.GillardM.LauransL.ValidireP.CaliandroR.MagdeleinatP.Mami-ChouaibF.Dieu-NosjeanM.-C.FridmanW.-H.DamotteD.Sautès-FridmanC.CremerI.Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance201012041285129710.1172/jci365512-s2.0-77951196379MoreiraD.ZhangQ.HossainD. M. S.NechaevS.LiH.KowolikC. M.D'ApuzzoM.FormanS.JonesJ.PalS. K.KortylewskiM.TLR9 signaling through NF-κB/RELA and STAT3 promotes tumor-propagating potential of prostate cancer cells2015619173021731310.18632/oncotarget.40292-s2.0-84938254969OchiA.GraffeoC. S.ZambirinisC. P.RehmanA.HackmanM.FallonN.BarillaR. M.HenningJ. R.JamalM.RaoR.GrecoS.DeutschM.Medina-ZeaM. V.SaeedU. B.Ego-OsualaM. O.HajduC.MillerG.Toll-like receptor 7 regulates pancreatic carcinogenesis in mice and humans201212211411841292302370310.1172/JCI636062-s2.0-8486862714523023703SongE.-J.KangM.-J.KimY.-S.KimS.-M.LeeS.-E.KimC.-H.KimD.-J.ParkJ.-H.Flagellin promotes the proliferation of gastric cancer cells via the Toll-like receptor 520112811151192145555810.3892/ijmm.2011.6562-s2.0-7995587208021455558González-ReyesS.FernándezJ. M.GonzálezL. O.AguirreA.SuárezA.GonzálezJ. M.EscaffS.VizosoF. J.Study of TLR3, TLR4, and TLR9 in prostate carcinomas and their association with biochemical recurrence20116022172262097888810.1007/s00262-010-0931-02-s2.0-7915148560520978888CammarotaR.BertoliniV.PennesiG.BucciE. O.GottardiO.GarlandaC.LaghiL.BarberisM. C.SessaF.NoonanD. M.AlbiniA.The tumor microenvironment of colorectal cancer: stromal TLR-4 expression as a potential prognostic marker20108, article 11210.1186/1479-5876-8-1122-s2.0-78049484534ChenX.ZhaoF.ZhangH.ZhuY.WuK.TanG.Significance of TLR4/MyD88 expression in breast cancer201586703470392-s2.0-84938582182MaF.-J.LiuZ.-B.HuX.LingH.LiS.WuJ.ShaoZ.-M.Prognostic value of myeloid differentiation primary response 88 and toll-like receptor 4 in breast cancer patients2014910e1116392536069910.1371/journal.pone.01116392-s2.0-8490999470125360699ChatterjeeS.CrozetL.DamotteD.IribarrenK.SchrammC.AlifanoM.LupoA.Cherfils-ViciniJ.GocJ.KatsahianS.YounesM.Dieu-NosjeanM. C.FridmanW. H.Sautès-FridmanC.CremerI.TLR7 promotes tumor progression, chemotherapy resistance, and poor clinical outcomes in non-small cell lung cancer20147418500850182507461410.1158/0008-5472.CAN-13-26982-s2.0-8490749968125074614BergerR.FieglH.GoebelG.ObexerP.AusserlechnerM.DopplerW.Hauser-KronbergerC.ReitsamerR.EgleD.ReimerD.Müller-HolznerE.JonesA.WidschwendterM.Toll-like receptor 9 expression in breast and ovarian cancer is associated with poorly differentiated tumors20101014105910662015621410.1111/j.1349-7006.2010.01491.x2-s2.0-7795726998620156214WangC.CaoS.YanY.YingQ.JiangT.XuK.WuA.TLR9 expression in glioma tissues correlated to glioma progression and the prognosis of GBM patients201010, article no. 4152069608110.1186/1471-2407-10-4152-s2.0-7795528868620696081DajonM.IribarrenK.CremerI.Toll-like receptor stimulation in cancer: a pro- and anti-tumor double-edged sword201722218910010.1016/j.imbio.2016.06.009VoulgarelisM.IoannouS.Toll-like receptors, tissue injury, and tumourigenesis20102010958183710.1155/2010/5818372-s2.0-77957832280RidnourL. A.ChengR. Y. S.SwitzerC. H.HeineckeJ. L.AmbsS.GlynnS.YoungH. A.TrinchieriG.WinkD. A.Molecular pathways: toll-like receptors in the tumor microenvironment—poor prognosis or new therapeutic opportunity20131961340134610.1158/1078-0432.ccr-12-04082-s2.0-84875189381ChefetzI.AlveroA. B.HolmbergJ. C.LebowitzN.CraveiroV.Yang-HartwichY.YinG.SquillaceL.SoterasM. G.AldoP.MorG.TLR2 enhances ovarian cancer stem cell self-renewal and promotes tumor repair and recurrence20131235115212332434410.4161/cc.234062-s2.0-8487542990623324344JiaD.YangW.LiL.LiuH.TanY.OoiS.ChiL.FilionL. G.FigeysD.WangL.β-Catenin and NF-κB co-activation triggered by TLR3 stimulation facilitates stem cell-like phenotypes in breast cancer201522229831010.1038/cdd.2014.1452-s2.0-84929460999LiuW.-T.JingY.-Y.YuG.-F.HanZ.-P.YuD.-D.FanQ.-M.YeF.LiR.GaoL.ZhaoQ.-D.WuM.-C.WeiL.-X.Toll like receptor 4 facilitates invasion and migration as a cancer stem cell marker in hepatocellular carcinoma201535821361432551173710.1016/j.canlet.2014.12.0192-s2.0-8492144208225511737LiuM.SakamakiT.CasimiroM. C.WillmarthN. E.QuongA. A.JuX.OjeifoJ.JiaoX.YeowW.-S.KatiyarS.ShirleyL. A.JoyceD.LisantiM. P.AlbaneseC.PestellR. G.The canonical NF-κB pathway governs mammary tumorigenesis in transgenic mice and tumor stem cell expansion2010702410464104732115965610.1158/0008-5472.CAN-10-07322-s2.0-7865036989321159656Uthaya KumarD. B.ChenC.LiuJ.FeldmanD. E.SherL. S.FrenchS.DiNorciaJ.FrenchS. W.NainiB. V.JunrungseeS.AgopianV. G.ZarrinparA.MachidaK.TLR4 signaling via NANOG cooperates with STAT3 to activate Twist1 and promote formation of tumor-initiating stem-like cells in livers of mice2016150370771910.1053/j.gastro.2015.11.002WangL.LiuZ.BalivadaS.ShresthaT.BossmannS.PyleM.PappanL.ShiJ.TroyerD.Interleukin-1β and transforming growth factor-β cooperate to induce neurosphere formation and increase tumorigenicity of adherent LN-229 glioma cells201231, article 510.1186/scrt962-s2.0-84863382046LiY.WangL.PappanL.Galliher-BeckleyA.ShiJ.IL-1β promotes stemness and invasiveness of colon cancer cells through Zeb1 activation201211, article 8710.1186/1476-4598-11-872-s2.0-84869875206StorciG.SansoneP.MariS.D'UvaG.TavolariS.GuarnieriT.TaffurelliM.CeccarelliC.SantiniD.ChiecoP.MarcuK. B.BonafèM.TNFalpha up-regulates SLUG via the NF-kappaB/HIF1alpha axis, which imparts breast cancer cells with a stem cell-like phenotype2010225368269110.1002/jcp.222642-s2.0-77957735709GuzmanM. L.NeeringS. J.UpchurchD.GrimesB.HowardD. S.RizzieriD. A.LugerS. M.JordanC. T.Nuclear factor-κB is constitutively activated in primitive human acute myelogenous leukemia cells2001988230123071158802310.1182/blood.V98.8.23012-s2.0-003588602411588023AlveroA. B.ChenR.FuH.-H.MontagnaM.SchwartzP. E.RutherfordT.SilasiD.-A.SteffensenK. D.WaldstromM.VisintinI.MorG.Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance20098115816610.4161/cc.8.1.75332-s2.0-60749103183MurohashiM.HinoharaK.KurodaM.IsagawaT.TsujiS.KobayashiS.UmezawaK.TojoA.AburataniH.GotohN.Gene set enrichment analysis provides insight into novel signalling pathways in breast cancer stem cells201010212062121999710610.1038/sj.bjc.66054682-s2.0-7424908830119997106ShipitsinM.CampbellL. L.ArganiP.WeremowiczS.Bloushtain-QimronN.YaoJ.NikolskayaT.SerebryiskayaT.BeroukhimR.HuM.HalushkaM. K.SukumarS.ParkerL. M.AndersonK. S.HarrisL. N.GarberJ. E.RichardsonA. L.SchnittS. J.NikolskyY.GelmanR. S.PolyakK.Molecular definition of breast tumor heterogeneity200711325927310.1016/j.ccr.2007.01.0132-s2.0-33847419142BoumahdiS.DriessensG.LapougeG.RoriveS.NassarD.Le MercierM.DelatteB.CaauweA.LenglezS.NkusiE.BrohéeS.SalmonI.DuboisC.MarmolV. D.FuksF.BeckB.BlanpainC.SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma201451175082462502490999410.1038/nature133052-s2.0-8490424624524909994ChiouS.-H.YuC.-C.HuangC.-Y.LinS.-C.LiuC.-J.TsaiT.-H.ChouS.-H.ChienC.-S.KuH.-H.LoJ.-F.Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma20081413408540951859398510.1158/1078-0432.CCR-07-44042-s2.0-4824910553118593985KumarS. M.LiuS.LuH.ZhangH.ZhangP. J.GimottyP. A.GuerraM.GuoW.XuX.Acquired cancer stem cell phenotypes through Oct4-mediated dedifferentiation201231474898491110.1038/onc.2011.6562-s2.0-84870063669YehD.ChenY.LaiC.LiuY.LuC.LoJ.ChenL.HsuL.LuoY.XiangR.ChuangT.Downregulation of COMMD1 by miR-205 promotes a positive feedback loop for amplifying inflammatory- and stemness-associated properties of cancer cells201523584185210.1038/cdd.2015.147NabetaniA.HatadaI.MorisakiH.OshimuraM.MukaiT.Mouse U2af1-rs1 is a neomorphic imprinted gene1997172789798900123310.1128/MCB.17.2.7892-s2.0-00310391809001233BartuziP.HofkerM. H.van de SluisB.Tuning NF-κB activity: a touch of COMMD proteins20131832122315232110.1016/j.bbadis.2013.09.0142-s2.0-84885059190MaineG. N.BursteinE.COMMD proteins: COMMing to the scene20076415199720051749724310.1007/s00018-007-7078-y2-s2.0-3444762378917497243MaineG. N.BursteinE.COMMD proteins and the control of the NFκB pathway20076667267610.4161/cc.6.6.39892-s2.0-34047225837StrebovskyJ.WalkerP.LangR.DalpkeA. H.Suppressor of cytokine signaling 1 (SOCS1) limits NFκB signaling by decreasing p65 stability within the cell nucleus201125386387410.1096/fj.10-1705972-s2.0-79954626520NakagawaR.NakaT.TsutsuiH.FujimotoM.KimuraA.AbeT.SekiE.SatoS.TakeuchiO.TakedaK.AkiraS.YamanishiK.KawaseI.NakanishiK.KishimotoT.SOCS-1 participates in negative regulation of LPS responses20021756776871243337310.1016/S1074-7613(02)00449-12-s2.0-1874437105012433373